Cargando…

Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma

The RAS-RAF-MEK-ERK pathway is hyperactivated in most malignant melanomas, and mutations in BRAF or NRAS account for most of these cases. BRAF inhibitors (BRAFi) are highly efficient for treating patients with BRAF(V600E) mutations, but tumours frequently acquire resistance within a few months. Mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Romano, David, García-Gutiérrez, Lucía, Aboud, Nourhan, Duffy, David J, Flaherty, Keith T, Frederick, Dennie T, Kolch, Walter, Matallanas, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434705/
https://www.ncbi.nlm.nih.gov/pubmed/36038253
http://dx.doi.org/10.26508/lsa.202201445